10-Q 1 vrtx-20220331.htm 10-Q vrtx-20220331
VERTEX PHARMACEUTICALS INC / MA000087532012/312022Q1falseP1M00008753202022-01-012022-03-3100008753202022-04-29xbrli:shares0000875320us-gaap:ProductMember2022-01-012022-03-31iso4217:USD0000875320us-gaap:ProductMember2021-01-012021-03-310000875320vrtx:CollaborativeandRoyaltyMember2022-01-012022-03-310000875320vrtx:CollaborativeandRoyaltyMember2021-01-012021-03-3100008753202021-01-012021-03-31iso4217:USDxbrli:shares00008753202022-03-3100008753202021-12-310000875320us-gaap:CommonStockMember2020-12-310000875320us-gaap:AdditionalPaidInCapitalMember2020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000875320us-gaap:RetainedEarningsMember2020-12-3100008753202020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000875320us-gaap:RetainedEarningsMember2021-01-012021-03-310000875320us-gaap:CommonStockMember2021-01-012021-03-310000875320us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000875320us-gaap:CommonStockMember2021-03-310000875320us-gaap:AdditionalPaidInCapitalMember2021-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000875320us-gaap:RetainedEarningsMember2021-03-3100008753202021-03-310000875320us-gaap:CommonStockMember2021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000875320us-gaap:RetainedEarningsMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000875320us-gaap:RetainedEarningsMember2022-01-012022-03-310000875320us-gaap:CommonStockMember2022-01-012022-03-310000875320us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000875320us-gaap:CommonStockMember2022-03-310000875320us-gaap:AdditionalPaidInCapitalMember2022-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000875320us-gaap:RetainedEarningsMember2022-03-31vrtx:segment0000875320vrtx:TRIKAFTAKAFTRIOMember2022-01-012022-03-310000875320vrtx:TRIKAFTAKAFTRIOMember2021-01-012021-03-310000875320vrtx:SYMDEKOSYMKEVIMember2022-01-012022-03-310000875320vrtx:SYMDEKOSYMKEVIMember2021-01-012021-03-310000875320vrtx:ORKAMBIMember2022-01-012022-03-310000875320vrtx:ORKAMBIMember2021-01-012021-03-310000875320vrtx:KalydecoMember2022-01-012022-03-310000875320vrtx:KalydecoMember2021-01-012021-03-310000875320country:US2022-01-012022-03-310000875320country:US2021-01-012021-03-310000875320srt:EuropeMember2022-01-012022-03-310000875320srt:EuropeMember2021-01-012021-03-310000875320vrtx:OtherNonU.S.Member2022-01-012022-03-310000875320vrtx:OtherNonU.S.Member2021-01-012021-03-310000875320us-gaap:NonUsMember2022-01-012022-03-310000875320us-gaap:NonUsMember2021-01-012021-03-310000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-31vrtx:target0000875320vrtx:CRSIPRARJDCAMember2021-04-012021-06-300000875320vrtx:CRSIPRARJDCAMember2021-07-01xbrli:pure0000875320vrtx:CRISPRMembervrtx:CRSIPRARJDCAMember2021-07-010000875320vrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000875320vrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-03-310000875320vrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000875320vrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-03-310000875320us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000875320us-gaap:EmployeeStockOptionMember2021-01-012021-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310000875320us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000875320us-gaap:EmployeeStockOptionMember2021-01-012021-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:CashAndCashEquivalentsMembervrtx:CashAndMoneyMarketFundsMember2022-03-310000875320us-gaap:CashAndCashEquivalentsMembervrtx:CashAndMoneyMarketFundsMember2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:CashAndCashEquivalentsMember2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:CashAndCashEquivalentsMember2022-03-310000875320us-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:USTreasurySecuritiesMembervrtx:MarketableSecuritiesMember2022-03-310000875320us-gaap:USTreasurySecuritiesMembervrtx:MarketableSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-03-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-03-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2021-12-310000875320vrtx:MarketableSecuritiesMember2022-03-310000875320vrtx:MarketableSecuritiesMember2021-12-3100008753202021-01-012021-06-300000875320us-gaap:OtherAssetsMember2022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310000875320us-gaap:CashFlowHedgingMembersrt:MinimumMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-03-310000875320us-gaap:CashFlowHedgingMembersrt:MaximumMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-03-310000875320currency:EURus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320currency:EURus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMembercurrency:GBPus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMembercurrency:GBPus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2021-12-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembercurrency:CHFus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembercurrency:CHFus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-01-012021-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:RestrictedStockMember2022-01-012022-03-310000875320us-gaap:RestrictedStockMember2021-01-012021-03-310000875320us-gaap:EmployeeStockMember2022-01-012022-03-310000875320us-gaap:EmployeeStockMember2021-01-012021-03-310000875320us-gaap:CostOfSalesMember2022-01-012022-03-310000875320us-gaap:CostOfSalesMember2021-01-012021-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310000875320vrtx:ShareRepurchaseProgram2020Member2020-11-300000875320vrtx:ShareRepurchaseProgram2020Member2021-01-012021-03-310000875320vrtx:ShareRepurchaseProgram2021Member2021-06-300000875320vrtx:ShareRepurchaseProgram2021Member2022-01-012022-03-310000875320vrtx:ShareRepurchaseProgram2021Member2022-03-31vrtx:credit_agreement0000875320us-gaap:RevolvingCreditFacilityMember2019-09-300000875320us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2019-09-012019-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2019-09-012019-09-300000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMembersrt:MinimumMember2019-09-012019-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2019-09-012019-09-300000875320us-gaap:LetterOfCreditMember2019-09-300000875320us-gaap:RevolvingCreditFacilityMember2020-09-300000875320us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2020-09-012020-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2020-09-012020-09-300000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMembersrt:MinimumMember2020-09-012020-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2020-09-012020-09-300000875320us-gaap:RevolvingCreditFacilityMember2020-09-012020-09-300000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or organization)

50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)

02210
(Zip Code)

Registrant’s telephone number, including area code (617341-6100
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No  
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
255,755,961
Outstanding at April 29, 2022


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2022

TABLE OF CONTENTS
Page
Condensed Consolidated Statements of Operations - Three Months Ended March 31, 2022 and 2021
Condensed Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2022 and 2021
Condensed Consolidated Balance Sheets - March 31, 2022 and December 31, 2021
Condensed Consolidated Statements of Shareholders' Equity - Three Months Ended March 31, 2022 and 2021
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2022 and 2021
Item 1A.

“Vertex,” “we,” “us,” and “our” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®” and “TRIKAFTA®” are registered trademarks of Vertex. The trademark for “KAFTRIOTM” is pending in the United States and registered in the European Union. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.



Part I. Financial Information

Item 1.  Financial Statements

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in millions, except per share amounts)
Three Months Ended March 31,
20222021
Revenues:
Product revenues, net$2,097.5 $1,723.3 
Other revenues 1.0 
Total revenues2,097.5 1,724.3 
Costs and expenses:
Cost of sales245.8 192.3 
Research and development expenses603.1 456.0 
Selling, general and administrative expenses215.2 192.1 
Change in fair value of contingent consideration(7.5)(3.9)
Total costs and expenses1,056.6 836.5 
Income from operations1,040.9 887.8 
Interest income1.6 1.5 
Interest expense(14.9)(15.7)
Other expense, net(72.8)(52.7)
Income before provision for income taxes954.8 820.9 
Provision for income taxes192.7 167.8 
Net income$762.1 $653.1 
Net income per common share:
Basic$2.99 $2.52 
Diluted$2.96 $2.49 
Shares used in per share calculations:
Basic255.1 259.4 
Diluted257.9 261.9 
The accompanying notes are an integral part of these condensed consolidated financial statements.

1

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(in millions)
Three Months Ended March 31,
20222021
Net income$762.1 $653.1 
Other comprehensive (loss) income:
Unrealized holding losses on marketable securities, net
(2.3)(0.2)
Unrealized gains on foreign currency forward contracts, net of tax of $(2.2) million and $(9.3) million, respectively
10.1 34.0 
Foreign currency translation adjustment(12.4)1.4 
Total other comprehensive (loss) income
(4.6)35.2 
Comprehensive income$757.5 $688.3 
The accompanying notes are an integral part of these condensed consolidated financial statements.

2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in millions, except share data)
March 31,December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$7,600.1 $6,795.0 
Marketable securities638.0 729.9 
Accounts receivable, net1,292.8 1,136.8 
Inventories338.9 353.1 
Prepaid expenses and other current assets
491.5 545.8 
Total current assets
10,361.3 9,560.6 
Property and equipment, net1,107.4 1,094.1 
Goodwill1,002.2 1,002.2 
Intangible assets
400.0 400.0 
Deferred tax assets
945.5 934.5 
Operating lease assets
329.0 330.3 
Other assets
110.7 110.8 
Total assets
$14,256.1 $13,432.5 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$173.6 $195.0 
Accrued expenses1,720.5 1,678.6 
Other current liabilities
286.1 268.4 
Total current liabilities
2,180.2 2,142.0 
Long-term finance lease liabilities495.5 509.8 
Long-term operating lease liabilities377.0 377.4 
Long-term contingent consideration
179.0 186.5 
Other long-term liabilities
117.4 116.8 
Total liabilities
3,349.1 3,332.5 
Commitments and contingencies  
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
  
Common stock, $0.01 par value; 500,000,000 shares authorized, 255,574,961 and 254,479,046 shares issued and outstanding, respectively
2.6 2.5 
Additional paid-in capital6,930.2 6,880.8 
Accumulated other comprehensive income11.3 15.9 
Retained earnings
3,962.9 3,200.8 
Total shareholders’ equity
10,907.0 10,100.0 
Total liabilities and shareholders’ equity
$14,256.1 $13,432.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(unaudited)
(in millions)
Three Months Ended
Common Stock
Additional
Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Total
Shareholders’ Equity
Shares
Amount
Balance at December 31, 2020259.9 $2.6 $7,894.0 $(68.5)$858.7 $8,686.8 
Other comprehensive income, net of tax
— — — 35.2 — 35.2 
Net income
— — — — 653.1 653.1 
Repurchase of common stock(2.0)0.0 (424.9)— — (424.9)
Common stock withheld for employee tax obligations(0.5)0.0 (102.1)— — (102.1)
Issuance of common stock under benefit plans1.4 0.0 15.2 — — 15.2 
Stock-based compensation expense
— — 117.0 — — 117.0 
Balance at March 31, 2021258.8 $2.6 $7,499.2 $(33.3)$1,511.8 $8,980.3 
Balance at December 31, 2021254.5 $2.5 $6,880.8 $15.9 $3,200.8 $10,100.0 
Other comprehensive loss, net of tax— — — (4.6)— (4.6)
Net income
— — — — 762.1 762.1 
Common stock withheld for employee tax obligations(0.5)0.0 (117.5)— — (117.5)
Issuance of common stock under benefit plans1.6 0.1 36.4 — — 36.5 
Stock-based compensation expense
— — 130.5 — — 130.5 
Balance at March 31, 2022255.6 $2.6 $6,930.2 $11.3 $3,962.9 $10,907.0 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in millions)
Three Months Ended March 31,
20222021
Cash flows from operating activities:
Net income
$762.1 $653.1 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense130.3 115.2 
Depreciation expense35.9 28.8 
Decrease in fair value of contingent consideration(7.5)(3.9)
Deferred income taxes(12.3)57.0 
Losses on equity securities75.6 52.3 
Other non-cash items, net4.9 2.3 
Changes in operating assets and liabilities:
Accounts receivable, net(165.2)(98.4)
Inventories2.0 (22.8)
Prepaid expenses and other assets67.6 (13.3)
Accounts payable(14.5)(10.6)
Accrued expenses61.6 153.0 
Other liabilities15.7 8.3 
Net cash provided by operating activities
956.2 921.0 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(117.1)(121.5)
Maturities of available-for-sale debt securities129.7 118.1 
Purchases of property and equipment(63.6)(70.9)
Net cash used in investing activities
(51.0)(74.3)
Cash flows from financing activities:
Issuances of common stock under benefit plans33.7 15.6 
Repurchases of common stock
 (424.9)
Payments in connection with common stock withheld for employee tax obligations
(117.5)(102.1)
Payments on finance leases
(12.9)(12.2)
Proceeds from finance leases
 3.6 
Other financing activities1.3 1.3 
Net cash used in financing activities
(95.4)(518.7)
Effect of changes in exchange rates on cash
(5.9)(4.0)
Net increase in cash, cash equivalents and restricted cash803.9 324.0 
Cash, cash equivalents and restricted cash—beginning of period
6,800.1 5,988.9 
Cash, cash equivalents and restricted cash—end of period
$7,604.0 $6,312.9 
Supplemental disclosure of cash flow information:
Cash paid for interest
$13.7 $14.5 
Cash paid for income taxes
$85.0 $10.7 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

A.Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.


6

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
B.Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
TRIKAFTA/KAFTRIO$1,761.6 $1,193.2 
SYMDEKO/SYMKEVI64.8 125.1 
ORKAMBI132.1 218.7 
KALYDECO139.0 186.3 
Total product revenues, net$2,097.5 $1,723.3 
Product Revenues by Geographic Location
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
United States$1,368.2 $1,253.4 
Outside of the United States
Europe632.3 405.0 
Other
97.0 64.9 
Total product revenues outside of the United States729.3 469.9 
Total product revenues, net
$2,097.5 $1,723.3 
Contract Liabilities
We had contract liabilities of $186.1 million and $171.7 million as of March 31, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.


7

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
C.Collaborative and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. In the three months ended March 31, 2022 and 2021, our “Research and development expenses” included $2.0 million and $1.7 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2022 and 2021, or were new or materially revised during the three months ended March 31, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities.

8

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to CTX001 pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, we recognized the following amounts in total related to these agreements:
Three Months Ended March 31,
20222021
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$76.6 $40.0 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
46.0 20.0 
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”


9

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
D.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20222021
(in millions, except per share amounts)
Net income$762.1 $653.1 
Basic weighted-average common shares outstanding255.1 259.4 
Effect of potentially dilutive securities:
Stock options1.3 1.2 
Restricted stock units (including PSUs)
1.4 1.3 
Employee stock purchase program
0.1 0.0 
Diluted weighted-average common shares outstanding257.9 261.9 
Basic net income per common share$2.99 $2.52 
Diluted net income per common share$2.96 $2.49 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20222021
(in millions)
Stock options0.0 0.4 
Unvested restricted stock units (including PSUs)0.6 0.7 

E.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.

10

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively):
As of March 31, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds
$4,378.6 $4,378.6 $ $ $3,478.1 $3,478.1 $ $ 
Commercial paper14.2  14.2      
Marketable securities:
Corporate equity securities155.3 155.3   230.9 230.9   
U.S. Treasury securities154.3 154.3   86.4 86.4   
Government-sponsored enterprise securities
7.0 7.0   69.0 69.0   
Corporate debt securities
76.8  76.8  90.9  90.9  
Commercial paper
244.6  244.6  252.7  252.7  
Prepaid expenses and other current assets:
Foreign currency forward contracts57.2  57.2  44.5  44.5  
Other assets:
Foreign currency forward contracts0.9  0.9  2.0  2.0  
Total financial assets
$5,088.9 $4,695.2 $393.7 $ $4,254.5 $3,864.4 $390.1 $ 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(5.1)$ $(5.1)$ $(5.6)$ $(5.6)$ 
Long-term contingent consideration
(179.0)  (179.0)(186.5)  (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(2.6) (2.6) (2.7) (2.7) 
Total financial liabilities
$(186.7)$ $(7.7)$(179.0)$(194.8)$ $(8.3)$(186.5)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 2.9% and 3.3% as of March 31, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future,

11

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(7.5)
Balance at March 31, 2022$179.0 

F.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively), is shown below:
As of March 31, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,378.6 $ $ $4,378.6 $3,478.1 $ $ $3,478.1 
Commercial paper14.2   14.2     
Total cash equivalents
$4,392.8 $ $ $4,392.8 $3,478.1 $ $ $3,478.1 
Marketable securities:
U.S. Treasury securities$155.7 $ $(1.4)$154.3 $86.6 $ $(0.2)$86.4 
Government-sponsored enterprise securities
7.1  (0.1)7.0 69.0   69.0 
Corporate debt securities
77.4  (0.6)76.8 91.1  (0.2)90.9 
Commercial paper
245.3  (0.7)244.6 252.8  (0.1)252.7 
Total marketable debt securities
485.5  (2.8)482.7 499.5  (0.5)499.0 
Corporate equity securities
69.4 92.2 (6.3)155.3 69.4 167.1 (5.6)230.9 
Total marketable securities
$554.9 $92.2 $(9.1)$638.0 $568.9 $167.1 $(6.1)$729.9 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$4,392.8 $3,478.1 
Marketable securities
482.7 499.0 
Total
$4,875.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Matures within one year$4,819.8 $3,912.3 
Matures after one year through five years
55.7 64.8 
Total
$4,875.5 $3,977.1 

12

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We have a limited number of available-for-sale debt securities in insignificant loss positions as of March 31, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2022 and 2021.
We record changes in the fair value of our investments in corporate equity securities to “Other expense, net” in our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, our net unrealized losses on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20222021
(in millions)
Net unrealized losses
$(75.6)$(52.3)
As of March 31, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $85.8 million.

G.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Foreign Currency Translation AdjustmentUnrealized Holding Gains (Losses), Net of TaxTotal
On Available-For-Sale Debt SecuritiesOn Foreign Currency Forward Contracts
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)  (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications1.4 (0.2)21.0 22.2 
Amounts reclassified from accumulated other comprehensive income (loss)  13.0 13.0 
Net current period other comprehensive income (loss)1.4 (0.2)34.0 35.2 
Balance at March 31, 2021$(14.2)$0.1 $(19.2)$(33.3)

H.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our

13

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2022, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,542.6 $1,364.5 
British pound sterling
283.7 287.7 
Canadian dollar
170.2 89.9 
Australian dollar
102.1 96.3 
Swiss Franc57.0 54.1 
Total foreign currency forward contracts
$2,155.6 $1,892.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other expense, net” in our condensed consolidated statements of operations each period. As of March 31, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $527.2 million.

14

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
During the three months ended March 31, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended March 31,
20222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$20.1 $(16.5)
Not designated as hedging instruments
Other expense, net$(8.4)$(8.0)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,097.5 $1,723.3 
Other expense, net$(72.8)$(52.7)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$57.2 Other current liabilities$(5.1)
Other assets0.9 Other long-term liabilities(2.6)
Total assets
$58.1 
Total liabilities
$(7.7)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of March 31, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.